Journal of Crohns & Colitis

Article	Citations
P470 Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease Patients	460
DOP59 Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore	250
P572 Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it’s time to make iron deficiency part of tight monitoring to reach T2T? – preliminary r	212
P554 Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?	116
P588 Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients	103
P678 Definition of a microbial signature as a predictor of post-surgical recurrence in patients with Crohn’s disease	100
P664 Bidirectional association between inflammatory bowel disease and psoriasis in a pediatric population: A nationwide insurance claim data analysis in South Korea	91
P622 Comparison of midterm outcomes in Pediatric Crohn’s Disease patients treated with either Exclusive Enteral Nutrition or Corticosteroids around disease diagnosis– a population based study	86
P135 Proximal Extension of lower rectal Ulcerative Proctitis	84
P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice	67
P574 Exploring treatment of Crohn’s disease and ulcerative colitis in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study	66
DOP87 Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s Disease	63
DOP35 Ambulatory care management of 70 patients with Acute Severe Ulcerative Colitis in comparison to 700 inpatients: Insights from a multicentre UK cohort study	60
P350 SAFIIR: Study of Anemia Following Intravenous Iron Repletion	57
P132 An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease	57
P404 Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany	50
P175 Low relapse rates after biologic therapy discontinuation in a large real life cohort of IBD patients with initial severe disease: do biologics alter the natural history of disease?	49
P659 Colonoscopic screening of symptomatic patients suggests an emerging inflammatory bowel disease (IBD) in urban and rural south India	48
P341 Fracture risk in middle-age and older patients with inflammatory bowel disease: A Korean nationwide population-based cohort study	47
P518 Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID	46
P719 Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infection	45
P708 Ileal involvement defined by Montreal classification in Crohn’s disease is associated with a distinct microbial composition in ileal and colonic mucosa	45
P394 Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease	43
P452 Oral ciclosporin is a convenient, effective and safe rescue therapy in steroid refractory Acute Severe Ulcerative Colitis: A single tertiary centre experience	42
P697 Examining the regulatory role of epigenetic and transcriptomic alterations in anti-TNFα treatment response and disease progression in patients with Ulcerative Colitis	40

P466 Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab	39
P513 Treatment persistence in bio-naive patients with long-standing Crohn’s disease treated with first-line biologics: real-life data from a Croatian tertiary center	39
OP07 Artificial intelligence surpasses gastrointestinal experts in the classification of endoscopic severity among Ulcerative Colitis	38
Mass-Cytometry-Based Quantification of Global Histone Post-Translational Modifications at Single-Cell Resolution Across Peripheral Immune Cells in IBD	37
Keeping It Simple: Using Intestinal Ultrasound to Assess Ulcerative Colitis with a Novel UC-Ultrasound Index	36
Inequitable Access to IBD Therapies Extends Beyond Developing Nations	36
P623 The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study	36
P014 Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmission	36
P247 Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts	34
P354 Early treatment versus active surveillance after ileocolic resection in Crohn’s disease: a retrospective cohort study	34
P666 Trend of Lower gastrointestinal Endoscopy in Patients with Inflammatory Bowel Diseases: A Nationwide Population-Based Study in South Korea	33
DOP19 Urinary metabolome in newly diagnosed treatment-naïve Crohn’s Disease patients: Results from the IBDomics study	33
P172 Clinical characteristics of newly diagnosed adult patients with Crohn’s disease in Japan: Interim analysis of Inception cohort registry study of patients with Crohn’s disease (iCREST-CD)	32
P096 Which patients with known Crohn’s disease after an ileo-colonoscopy will benefit most from small bowel capsule endoscopy?	31
P223 Degree of Histological Activity is not Associated with Vedolizumab Therapy Outcome in Ulcerative Colitis	30
DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study	30
P664 Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)	30
P309 Withdrawal of thiopurines in Inflammatory Bowel Disease patients in stable remission: a prospective, multicentre cohort study	30
P269 Spaciotemporal machine learning analysis of complete small bowel capsule endoscopy videos for prediction of outcomes in Crohn’s disease	29
P184 Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study	29
P604 Evaluation of management heterogeneity and complications of Crohn’s disease in Catalonia. A population quality care study	29
P169 Vitamin D levels are inversely associated with inflammation in pediatric InflammatoryBowel Disease patients	29
P165 Characterization and risk of sarcopenia in patients with Ulcerative Colitis, compared with older and younger adults. Cross-sectional study	28
P481 Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project	28
P375 Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patients	27
P036 MicroRNA composition of colon crypt-top and crypt-bottom epithelial cells in Ulcerative Colitis	27
P595 Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease	27
P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents	26
P438 The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age	26
P032 Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients	26
P645 Ileocecal resection in paediatric Crohn’s disease based on the Hungarian Paediatric IBD Registry	26
P1091 Trends in length of stay and steroid use in patients admitted with Acute Severe Ulcerative Colitis: Impact of intensified or accelerated infliximab dosing	25
P200 Celiac disease (CD) and CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) association	25
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease	25
N12 Systematic Review: The role of psychological stress in Inflammatory Bowel Disease	25
P672 Biologic therapy for Inflammatory Bowel Disease in Poland in 2020: nationwide data	25
N09 Italian translation and validation of the Spiritual Needs Questionnaire - Extended Version in Inflammatory Bowel Disease: preliminary results	24
P1029 Janus Kinase Inhibitors for the Management of Acute Severe Ulcerative Colitis: A Multicentre Study	24
P1000 A quasi-experimental study evaluating effectiveness of partial enteral nutrition combined with exclusion diet in patients with mild to moderately severe ulcerative colitis	24
P0818 Addressing unmet needs in adult Inflammatory Bowel Disease care	23
P1075 Evaluation of characteristics of faecal urgency in patients with ulcerative colitis	23
P0855 Rise in admissions for Acute Severe Ulcerative Colitis at an Australian tertiary IBD centre with a culturally and linguistically diverse population: Implications for health resource planning	23
N40 Efficacy and safety of Risankizumab in moderate to severe paediatric Crohn’s disease in a tertiary Paediatric IBD (PIBD) centre – A case series	23
P1283 Adherence to Infectious Disease Assessment at Baseline in Patients with Inflammatory Bowel Disease: A Retrospective Study from a Medical Center	23
P0714 Low risk of recurrent or new neoplasia after immunomodulatory therapy in patients with Inflammatory Bowel Disease and previous cancer: a multicentre retrospective Italian study	23
P1257 Difficult-to-treat Inflammatory Bowel Disease in Latin American countries: prevalence and clinical characteristics.	22
P0691 Impact of Ozanimod (OZA) on Circulating Neutrophils: Results from the Phase 3 Japanese True North (J-TN) Study of Patients (Pts) With Moderately to Severely Active Ulcerative Colitis (UC)	22
P1135 Comparing Hypophosphataemia Risk and Complications Between Ferric Carboxymaltose and Other IV Iron Formulations in General and Inflammatory Bowel Disease Populations	22
P1317 Oral microbiota is linked to the propensity for mucosal healing: A prospective oral-gut-stool microbiome analysis in IBD	22
P1324 Longitudinal Changes in Gut Microbiota During the First Year following diagnosis of Inflammatory Bowel Disease – the IBSEN III study	22

P1349 Fungal profile of the gut colon - a new tool in diagnostics of ulcerative colitis remission	22
P1101 Real-world effectiveness and safety of Risankizumab in Crohn’s Disease	22
P1302 OCTN1 variants shape innate immunity and predict individual response to vedolizumab in ulcerative colitis patients: from preclinical models to AI	21
P1236 Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease	21
P1172 Real world experience using advanced therapies to treat Inflammatory Bowel Disease in patients with a Liver Transplant	21
P1245 Maternal intake of fish, dietary n-3 polyunsaturated fatty acids, and fish oil supplements during pregnancy and risk of early childhood Inflammatory Bowel Disease in the offspring	21
P1244 Differential impact of appendectomy with appendiceal inflammation versus no inflammation on inflammatory bowel disease risk in a population-based cohort	21
P1166 Factors associated with mesalamine refractory Ulcerative Proctitis requiring advanced medical treatments	21
P1331 Differences in gut microbiome comparing lifestyle habits between ulcerative colitis patients and healthy controls during COVID-19	20
P1289 Sleep Quality and Associated Factors in Patients with Inflammatory Bowel Disease: A Cross-Sectional Study	20
P1213 The role of stress in dietary choices and disease outcomes in Inflammatory Bowel Disease	20
P1192 Use of a mobile application for monitoring and communicating with Inflammatory Bowel Disease patients	20
P1118 Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from Taiwan	20
P1188 Real-world quality of life experience of subcutaneous infliximab use in children with Inflammatory Bowel Disease (IBD) at a tertiary paediatric centre	20
P1210 Risk of post-acute sequalae of COVID-19 in patients with immune-mediated inflammatory diseases	19
P1092 Real-life durability and utilization of biologics in pediatric inflammatory bowel disease: results from Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP) IBD regis	19
P1088 Positive effects of a mindfulness-based intervention on depression, stress and perceived control, but not on disability in patients with Crohn’s disease: results from a randomized controlled tri	19
N49 Sexual and reproductive health of Australian women who live with Inflammatory Bowel Disease	19
Targeting hypoxia-induced signaling via HIF-2 inhibition, a promising treatment strategy for intestinal fibrosis?	19
P1276 Persistent Insomnia Ignites the Flames of Crohn's Disease by Elevating Systemic Inflammation	19
P1248 Higher Life’s Essential 8 score is associated with reduced risk of IBD-related surgery and all-cause mortality among 3,232 individuals with inflammatory bowel disease in a prospective cohort stu	19
P1351 Microbiome Diversity and Taxonomic Differences in Quiescent Ulcerative Colitis: A Comparative Study of Proximal Extension	19
P1195 Ecological momentary assessment of fatigue and depressive symptoms reveals significant daily variability in IBD	19
P1208 High Prevalence of Perianal Crohn’s Disease and Distinct Advanced Therapy Persistence in an Arab IBD cohort	19
P1067 Comparison of AZA-Related Pancreatitis and AZA-Related GI Intolerance Based on Demographic Factors, Clinical Variables and HLA DQA1/DRB1 Alleles	19
Deciphering the role of the intestinal microbiota in mediating the protective effect of Exclusive Enteral Nutrition on patients with Crohn’s disease	19
P1181 Liver fibrosis predicts response to advanced therapy in inflammatory bowel disease: a new personalized treatment approach?	19
P1052 Ustekinumab for refractory intestinal Behçet’s Disease	18
P0824 Patient-Reported Outcomes in Chinese Patients with Inflammatory Bowel Disease treated with Vedolizumab: A subgroup analysis of second interim analysis of VALUE study	18
P0962 Relationship between Total Corticosteroid Dose Prior to Advanced Therapy Induction and Primary Non-Response	18
P0808 Early Top-down treatment improves transmural remission rates in Crohn's disease - a risk-adjusted propensity score matched analysis	18
P0265 A retrospective cohort study of pregnant women with Inflammatory Bowel Disease – outcomes from a multidisciplinary clinic in a tertiary centre	18
P0554 Machine Learning-Based Interpretation of Unstructured Radiology Reports for Objective Scoring of Inflammation and Stenosis in IBD: A Nationwide Study From the epi-IIRN	18
P0309 Machine learning for predicting Crohn’s disease from routine blood tests years before diagnosis: results from the epi-IIRN	18
P0885 Therapeutic Concepts for Pyoderma Gangrenosum as an Extraintestinal Manifestation in Chronic Inflammatory Bowel Diseases	18
P0930 Adalimumab is equally efficient as infliximab in achieving sustained remission in Ulcerative Colitis but inferior in patients with severe disease	18
P1071 Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study	18
N35 Psycological discomfort in patients with Inflammatory Bowel Disease	18
P0282 Fibroblast activation protein (FAP)-cleaved type III Collagen [C3F] is a potential marker for intestinal fibrosis in patients with Crohn’s Disease	18
P0829 ‘Temporary’ faecal diversion in refractory Crohn’s Disease: too good to be true? A retrospective, single centre analysis	18
P0731 Analysis of the short-term efficacy and risk factors of ustekinumab combined with surgical intervention in the management of perianal fistulizing Crohn's Disease: a single center real-world resu	17
P0935 A systematic review and quality assessment of clinical practice nursing guidelines for ostomy care	17
P0638 Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study	17
P0718 Ulcerative Proctitis: Adherence to Guidelines and confirmation of clinical, biochemical and endoscopic remission in phenotypically E1 patients.	17
P0651 Evaluating tryptophan as a biomarker for treatment success in Inflammatory Bowel Disease patients undergoing therapy	17
P0754 Extensive disease clearance as a novel composite endpoint to predict long-term relapse in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised cont	17
P0923 Impact of Inflammatory Bowel Disease on Women’s Health	17
P0928 Patient endotypes in ulcerative colitis revealed by longitudinal symptom trajectories under therapy	16
P1288 The Association of Long-term Night Shift Work and Related Circulating Proteins with Inflammatory Bowel Disease: A Prospective Cohort and Multi-omics Study	16
P0694 Clinical response trajectories identify distinct subpopulations of ulcerative colitis patients and are linked to disease outcome across different therapy classes. Patient level analysis of 2378	16
P1142 Time to clinical recapture after dose escalation of subcutaneous infliximab (CT-P13 SC) following loss of response: A post hoc analysis of the 2-year Phase 3 LIBERTY-CD & LIBERTY-UC trials	16
N45 The Words of Bowels: Exploring Crohn's Disease through Metaphors	16
Diagnostic Markers of Primary Sclerosing Cholangitis in Newly Diagnosed Patients with Inflammatory Bowel Disease - a Copenhagen IBD Inception Cohort Sub-study	16
P0702 Efficacy of subcutaneous infliximab maintenance therapy according to disease location in patients with moderate-to-severe Crohn’s disease: A post hoc analysis of the Phase 3 LIBERTY-CD study	16
P1140 Filgotinib effectiveness and safety in moderate and severely active patients with Ulcerative Colitis: early real-world outcomes in an interim analysis of data from the prospective, observational	16
P1074 Deep dive into an IBD service: mapping and identifying service gaps	16
P0753 Early surgery in pediatric-onset ileocecal Crohn’s disease is associated with less unfavourable disease course: a retrospective population-based study	15
N21 Clinical Nurse Specialist in Inflammatory Bowel Disease (CNS-IBD). Care challenges and economic sustainability. A Scoping review	15
P0880 Sphingosine 1-phosphate (S1P) Receptor Modulators for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	15
P1020 Trends in Opioid Use among Patients with Inflammatory Bowel Disease and Changes Following Advanced Therapy Initiation: A Korean nationwide population-based study	15
P0912 Factors associated with adherence to the Mediterranean diet in patients with Ulcerative Colitis after pouch surgery	15
P0793 Correlation between patient centred disease control versus biochemical parameters in IBD	15
P1338 Defining the preclinical changes of microbial composition, gut barrier function, and subclinical inflammatory markers associated with future risk of ulcerative colitis	15
N30 Exploring the effects of nurse-led clinics on the Inflammatory Bowel Disease service	15
P0742 Real-world efficacy and safety of Upadacitinib in IBD patients. Preliminary data from the Apulian Network for Inflammatory Bowel Disease (AN-IBD)	15
P1154 Impact of pharmacological therapies for moderate to severe Ulcerative Colitis on health-related quality of life: a systematic review and network meta-analysis	15
P1093 Personalized Tasty&Healthy whole-food diet for maintaining remission in children and adults with Crohn’s disease: results from the MyTasty open-label trial	15
P0640 Development and characterization of LQ080, a novel extended half-life bispecific TL1A/IL-23 p19 single domain antibody for the treatment of IBD	15
P1111 Infliximab is not Superior to Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colotis with PR3-ANCA Positive : A Retrospective Multicentre Real-World Study	15
P1017 Real-world effectiveness and safety of filgotinib with and without concomitant therapies in patients with Ulcerative Colitis: an interim analysis of the prospective, observational GALOCEAN study	15
P0646 Significant mental health and fatigue burden found in tertiary paediatric IBD service in Australia	14
P0789 Combined inhibition of TL1A and integrin β7 is superior to either monotherapy in mouse models of colitis and coadministration of SPY001 and SPY002 demonstrates no drug-drug effects on exposure i	14
P1262 Factors associated with bowel urgency in patients with inflammatory bowel disease – interims analysis of the Health Outcome Observatory (H2O) project	14
P0667 Therapeutic Optimization of Biologic Therapy in Ulcerative Colitis: A Retrospective Analysis of Endoscopic and Biomarker Outcomes	14
P1161 Effects of janus-kinase inhibitor therapy on lipid parameters in patients with IBD	14
P0970 Associations between diet, faecal and flatulence odour perception and disease activity in patients with inflammatory bowel disease and healthy controls	14
N33 Construction and Application of a Digital Management Platform for the Whole Course of Inflammatory Bowel Disease Patients Based on Action Research	14
P0695 Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe Ulcerative Colitis: A discrete choice experime	14
P0870 Efficacy and Safety of Different Doses of Adalimumab in Crohn's Disease: A Multicenter Cohort Study in Infliximab-Naïve and Infliximab-Exposed Patients	13
P0746 Impact of timing of prophylaxis therapy on post-operative endoscopic recurrence in a real-life cohort of patients whit Crohn’s disease	13

P0346 Pouch Fistulas: Experience From a Tertiary Center	13
P0204 Impact of crypt niche factors and oxygen gradient on intestinal epithelial differentiation and inflammatory response	13
P0606 The efficacy of upadacitinib in Intestinal Behçet’s Disease refractory to anti-TNF-α therapy in a retrospective study	13
P0931 Induction treatment with upadacitinib is associated with high rate of clinical response in patients with refractory Inflammatory Bowel Disease	13
P1021 Treatment Patterns for Crohn’s Disease: a Multinational Analysis from 2011 to 2022 in the United States, Japan, and China	13
P0676 Inborn Errors of Immunity Associated with Inflammatory Bowel Disease at a Tertiary Care Centre	13
P0238 Reliability of magnetic resonance imaging indices for evaluating perianal fistulizing disease activity in paediatric Crohn’s disease	13
P0386 Prevalence and Impact of Anorectal Disorders in IBD: Insights from a Romanian Tertiary Gastroenterology Center	13
P0819 AIRIS-Crohn: Results on the Effectiveness and Safety of Risankizumab in the Medium Term in Real-World Clinical Practice	13
P0807 Impact of Risankizumab on Patient-reported Outcomes and Biomarkers Over Time: Post-Hoc Analysis of Phase 3 INSPIRE and COMMAND Studies	13
P0711 The Effect of Extraintestinal Manifestations Presence on Treatment Persistence in IBD Treatment	13
P0584 Rituximab versus infliximab for the treatment of PR3-ANCA Positive Moderately to Severely Active Ulcerative Colotis: A retrospective Multicentre Real-World Study	13
P0514 Assessing the relationship between physician perspective and subjective disabilities in IBD patients: a comparative study using IBD-Disk and IBD-Q	13
P0752 Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label e	13
P0381 Correlation Between Rectal Endoscopic and Histological Involvement and the Prevalence and Severity of Ano-Perineal Lesions in Inflammatory Bowel Disease	12
P0050 4-Octyl Itaconate Protects Against Colitis by Modulating Neutrophil Function and Enhancing Intestinal Epithelial Barrier Integrity	12
P0181 Modulating macrophage activity via NAAA pharmacological inhibition: a therapeutic strategy for intestinal fibrosis	12
P0221 The role of caffeine and its metabolites in the modulation of intestinal inflammation and epithelial barrier integrity	12
P0411 Utility of Intestinal Ultrasound as a predictor of Severe Ulcerative Colitis response to treatment	12
P0406 Complications after ileal pouch-anal anastomosis in patients with Ulcerative Colitis and primary sclerosing cholangitis	12
P0730 Inflammatory Bowel Disease Lifestyle Food and Exercise (IBDLiFE) study: a randomized controlled trial to investigate the effectiveness of a personalised diet and physical activity intervention f	12
P0405 Evaluation of penetrating Crohn’s disease: course of complicated disease and risk factors associated with progression to penetrating complications	12
P0182 The systemic administration of the anti-MCL1, S63845, reduces inflammation and fibrosis in a murine model of DSS-Chronic Colitis	12
P0279 Assessing patient-reported health status in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Results from the communicating needs and features of IBD experiences (CONFIDE) survey	12
P0574 Correlations Between Inflammatory Biomarkers and Hematological Parameters in Assessing Disease Activity in IBD	12
P0360 Bowel Ultrasonography and Computed Tomography tell the same story using different languages in analizing Crohn’s disease lesions	12
P0110 Effect of Tofacitinib on Hemostasis in Patients with Ulcerative Colitis: a Comparative Ex Vivo Study	12
P0857 The Effectiveness of Ustekinumab in Treating Small Bowel Crohn’s Disease Assessed by Magnetic Resonance Enterology	12
P0964 The effect of alarms on completion of electronic diaries in patients with inflammatory bowel disease	12
P0303 Evaluation of the Terminal Ileum on Computed Tomography of Patients with Non-Traumatic Acute Abdominal Pain in the Emergency Department	12
P0784 Independent association between baseline simple endoscopic score for Crohn’s disease and C-reactive protein with Crohn’s disease-related complications: An analysis of the Randomized Evaluation o	12
P0003 Differential Effects of JAK Inhibitors on Epithelial-Immune Interaction in Inflammatory Bowel Disease	11
P0026 Multi-omics phenotyping characterizes perturbed molecular divergence underlying different clinical scenarios of under-treatment inflammatory bowel disease	11
P0439 Ultrasound transmural healing reduces the risk of relapse in Crohn’s disease patients with endoscopic mucosal healing: results of a prospective study	11
P0145 Role of PPARg on anti-inflammatory effects mediated by AhR ligands in a Caco-2/THP-1 in vitro “inflamed gut” model	11
P0202 Modeling Inflammatory Bowel Disease in mice with “Humanized” immune system	11
P0278 Healthcare resource utilization by patients with Difficult-to-Treat Inflammatory Bowel Disease in Latin American Countries.	11
P0453 Intestinal Ultrasound Correlates with Patient-Reported IBD Disability in Ulcerative Colitis: A Step Towards Integrated Monitoring	11
P0465 Chromoendoscopy for Dysplasia Detection in High-Risk IBD Patients: A Decade of Experience at a Tertiary Care Centre	11
P0600 Do GI Quant small bowel motility values correlate with reported MR enterography findings in Crohn’s disease?	11
P0542 Systematic Liver Biopsies in IBD Surgery: A Unique Insight into Silent Hepatic Abnormalities	11
DOP108 Inflammatory Bowel Disease and concomitant endometriosis: frequency and characteristics in a multidisciplinary approach	11
P0189 Microbial and Molecular Profiling of the appendix of pediatric patients with inflammatory bowel diseases	11
P0305 The Choice of Endoscopic Surveillance Strategies for IBD Patients Among Taiwanese Physicians: An Anonymous Questionnaire Survey	11
P0623 Vedolizumab clearance as a predictor of remission in inflammatory bowel disease: a real-world pharmacokinetic study	11
P0394 Sex- and phenotype-specific patient-reported outcomes and symptoms in newly diagnosed-inflammatory bowel diseases – a prospective population-based study	11
P0475 Differential characteristics and predictors of time to colectomy in ulcerative colitis: stratified by medical refractory disease vs. colitis-associated neoplasia	11
P0478 Peripheral blood cytokines in patients with paediatric-onset Inflammatory Bowel Disease – a systematic review and meta-analysis	11
DOP046 Effectiveness and Safety of Mirikizumab after switching from Ustekinumab in patients with moderate to severe Crohn’s disease: results from a long-term extension study	11
P0435 Comparative analysis between capsule endoscopy and ileocolonoscopy for activity detection in ileal Crohn’s disease. Preliminary results from the CAPITER study, a multicenter study from the Young	11
P0613 Obesity is associated with inferior treatment outcomes in inflammatory bowel disease: a nationwide Dutch registry study	11
P0490 Diagnosis and treatement of latent tuberculosis infection in patients with chronic Inflammatory Bowel Disease candidates for anti-TNFα therapy in a tuberculosis endemic country	11
P0543 Impact of disease clearance on the disease course in Ulcerative Colitis patients in clinical remission over a ten-year follow-up	11
P0228 Evolution of the IBD-Disability Index in a cohort of recently diagnosed CD patients: results from the prospective CROCO (Crohn´s Disease Cohort) Study	11
P0738 Apulian Network for Inflammatory Bowel Disease (AN-IBD) safety profile: Pilot data	11
P0301 The Prevalence and Association Between Immune-Mediated Inflammatory Disorders and Inflammatory Bowel Disease	11
P0397 Nutritional status and the risk of proctectomy in patients with perianal fistulising Crohn’s disease	10
P0701 Trans-continental analysis of determinants of response to COVID-19 vaccination in 2268 patients with Inflammatory Bowel Disease	10
P0500 Multi-Module Metaformer System for Distinguishing Crohn’s Disease from Intestinal Tuberculosis	10
P1301 Bile acid composition and immunological effect in mouse model and IBD patients	10
P1307 Variant in Complement Factor B is associated with perianal disease in Ulcerative Colitis	10
P0123 The immune system of patients with immune-mediated diseases perceives dysbiotic intestinal microbial species, and IgG reactivity uncovers shared and non-shared responses across diseases	10
DOP026 Porphyromonas gingivalis secreted htpG disrupts TLR4/ PAPSS2-mediated mucin sulfation and aggravates ulcerative colitis	10
P0961 Establishing a new cellular therapy for patients with Ulcerative Colitis	10
P1252 Prevalence, Incidence and Mortality of Pediatric Inflammatory Bowel Disease in Catalonia	10
P0989 Interventions for rheumatological extraintestinal manifestations in Inflammatory Bowel Disease: an umbrella review of systematic reviews	10
P0495 Impact of the HLA DQA1*05 allele on the efficacy of vedolizumab treatment in inflammatory bowel disease	10
P0250 Circulating blood matrix metalloproteinase (MMP)-10 and 12 can accurately predict mucosal healing in Inflammatory Bowel Disease (IBD) in a multi-centred prospective longitudinal cohort study (20	10
N10 “I probably am being a naughty boy, but…” Exploring reasons for non-adherence to prescribed medication, as perceived by people living with Inflammatory Bowel Disease: A Qualitative Study	10
P1220 Circulating Metabolite Signatures Linking Physical Activity to Inflammatory Bowel Disease Risk and Interactions with Genetic Susceptibility	10
DOP053 Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA)	10
P0778 Exploring the impact of personalised and curated educational videos delivered via an online platform to paediatric IBD patients	10
P0893 Angiopoietin-like Protein 8 (ANGPTL8) in Inflammatory Bowel Disease and Its Response to Anti-TNFα Therapy; A Prospective Multi Center Study	10
P1185 Preoperative bowel preparation in Crohn’s disease patients: final results of the prospective observational study	10
P1078 Weight-loss medications and bariatric surgery are infrequently used in obese patients with inflammatory bowel disease in North and East Devon in the United Kingdom (UK)	10
P0598 Feasibility and limitations in adopting treat-to-target approach in inflammatory bowel diseases (IBD): real-life scenario	10
P0635 Degree of interest in using a cognitive-behavioral therapy application for fatigue management and related factors among outpatients with inflammatory bowel disease	10
P0421 Clinical validity of a seroproteomic index of endoscopic activity in pediatric Crohn’s disease	10
P1235 COlombian PrevaLence of Extraintestinal Manifestations in Inflammatory bowel disease in an adult and pediatric cohort after evaluation by a multidisciplinary group COLEMI – study	10
P0089 Infra-red microspectroscopy provides quantitative assessment of fibro-inflammation in Crohn’s disease strictures and predicts post-operative recurrence	10
DOP111 Lack of epithelial RhoA in the gut, a new colitis-associated cancer experimental model	10
P0682 Effectiveness, safety and predictors of response to vedolizumab as first- or second-line biological therapy in patients with ulcerative colitis: A real-world observational multicenter study.	10
P0526 Association of plasma IgA with bowel wall thickness and disease activity in IBD patients assessed by intestinal ultrasound	10
P0619 Comparative efficacy of all available pharmaceutical therapies for moderate to severe Crohn’s disease: a systematic review and network meta-analysis	10
P1346 Response to biologic treatment in patients with Crohn’s disease is associated with consistent decreased antibody response to bacterial flagellins	10
N23 Volume and Impact of Text Communications with an IBD Nurse– A Large Tertiary Center Experience	10
P0391 The impact of point of care ultrasound on time to initiating advanced therapy in IBD (GUIDE-IBD): A randomised controlled trial	9
P0008 A multi-omics approach across multiple chronic inflammatory diseases identifies a distinct type-1-interferon endotype of Inflammatory Bowel Disease	9
P0111 Patient reported outcome measures (PROM) in patients scheduled to undergo bowel resection for Crohn’s disease	9
P0523 Comparative analysis of two ELISA methods for measuring serum ustekinumab levels in Inflammatory Bowel Disease ¿Is interchangeability feasible?	9
P0551 Diagnostic Accuracy of Low-Cost Blood Test Inflammatory Markers in Severe Ulcerative Colitis	9
P0485 Seroproteomic index of endoscopic activity associates with endoscopic outcomes in a longitudinal cohort of adults ulcerative colitis	9
P0463 Co-infection of Clostridium innocuum Worsens Outcomes in Inflammatory Bowel Disease Patients with Clostridioides difficile Infection	9
P0227 Uncontrolled clinical activity and anti-TNF plus thiopurine combination therapy are predictive factors of 1-year infection risk following acute severe ulcerative colitis: AOCC and ANZIBDC collab	9
P0116 The Protective Role of PYY in Intestinal Mucosal Defects Induced by SATB2 Deficiency in Inflammatory Bowel Disease	9